UK markets closed

Olema Pharmaceuticals, Inc. (OLMA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.32+0.12 (+1.07%)
At close: 04:00PM EDT
11.09 -0.23 (-2.03%)
After hours: 07:29PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.20
Open11.21
Bid11.30 x 200
Ask11.34 x 100
Day's range10.80 - 11.50
52-week range3.00 - 17.79
Volume469,652
Avg. volume812,040
Market cap632.954M
Beta (5Y monthly)2.14
PE ratio (TTM)N/A
EPS (TTM)-2.14
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.25
  • GlobeNewswire

    Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

    Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3 monotherapy trial in Q4 2023; top-line results expected in 202660-patient Phase 2 studies in combination with each of ribociclib and palbociclib are fully enrolled; palazestrant-ribociclib clinical update to be presented at ESMO Breast Cancer Annual Congress 2024, May 15-17, 2024, in BerlinCash, cash equi

  • GlobeNewswire

    Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

    Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250)Pre-clinical results demonstrate that palazestrant, as both a CERAN and a SERD, has a highly differentiated mechanism of action as a potential therapy for advanced ER+/HER2- breast cancer SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceut

  • GlobeNewswire

    Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to one new employee to purchase an aggregate of 50,000 shares of the Company's common stock, effective as of March 1, 2024. These awards were approved by the Compensation Comm